Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)
調査の概要
詳細な説明
Of the two currently available treatments for kidney failure, long-term dialysis and kidney transplantation, only kidney transplantation provides a potential cure. After a kidney transplant, the body's immune system recognizes the kidney as foreign and tries to attack and destroy it in a process called rejection. To avoid rejection, participants must take medications called immunosuppressants or anti-rejection drugs. It is believed that by transplanting bone marrow at the same time as a solid organ such as a kidney, a state of "mixed chimerism" (a mixing of the donor and recipient's immune system) can be achieved. Mixed chimerism may prevent rejection without the need for anti-rejection drugs.
Participants in this study will receive a simultaneous bone marrow and kidney transplant from the same living related donor in an attempt to establish mixed chimerism. Prior to transplantation, participants will undergo a "conditioning regimen" involving cyclophosphamide chemotherapy, radiation to the thymus gland, and four immunosuppressive medications: cyclosporine A, a man-made antibody known as rituximab to suppress B cells, a short course of steroids, and a T-cell depleting antibody known as MEDI-507. MEDI-507 is an investigational medication that has not been approved by the FDA. The primary goal of the study is to investigate the safety of the conditioning regimen and its ability to promote mixed chimerism so that the transplanted kidney is not destroyed. The study will also determine whether participants with mixed chimerism can eventually be safely removed from long-term immunosuppressive therapy following transplantation.
Participants will be assessed before and after transplantation and will be followed ≤36 months.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- End-stage renal disease (ESRD) without prior sensitization (defined as Panel Reactive Antibody [PRA] greater than 20%) within the 60 days prior to transplant as measured by cytotoxicity assays, ELISA, and flow cytometry;
- Undergoing a first or second transplant;
- Receiving a transplant from a living related donor who is ABO (blood type) compatible and haploidentical (3, 4, or 5 antigen match by serologic typing);
- Cardiac ejection fraction greater than 40%;
- Forced expiratory volume (FEV1) greater than 50%;
- Liver function tests, bilirubin, and coagulation studies less than 2 X normal;
- White blood cells greater than 2000/mm^3; abd
- Platelets greater than 100,000/mm^3
Exclusion Criteria:
- Positive donor lymphocyte cross-match;
- HIV-1 infected;
- Positive hepatitis B surface antigen (HbsAg);
- Hepatitis C virus infected;
- History of cancer;
- Prior dose-limiting radiation therapy;
- Pregnant, breastfeeding, or planning pregnancy within the time frame of the study;
- Enrolled in another investigational drug study within 30 days prior to study entry; or
- Receiving maintenance immunosuppression within 3 months before the conditioning regimen begins
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Conditioning Regimen
Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days. |
Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1.
Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow.
Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.
Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Graft Survival Twenty-Four Months Post Transplantation
時間枠:24 months (2 Years) Post Transplantation
|
Defined by kidney transplant survival at month 24 post transplantation with successful withdrawal of cyclosporine following transplantation, in the absence of maintenance immunosuppression.
|
24 months (2 Years) Post Transplantation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participant Survival
時間枠:Up to thirty-six months (3 Years) Post Transplantation
|
During the three-year post-transplant follow-up period for enrolled participants.
|
Up to thirty-six months (3 Years) Post Transplantation
|
|
Graft Survival
時間枠:Up to thirty-six months (3 Years) Post Transplantation
|
During the three-year post-transplant follow-up period for enrolled participants.
|
Up to thirty-six months (3 Years) Post Transplantation
|
|
Change from Baseline in Renal Function Using Serum Creatinine
時間枠:Up to thirty-six months (3 Years) Post Transplantation
|
Changes in serum creatinine levels from baseline through post transplantation follow-up period.
|
Up to thirty-six months (3 Years) Post Transplantation
|
|
Number of Episodes of Acute or Chronic Graft Versus Host Disease (GVHD)
時間枠:From Week 1 through thirty-six months (3 Years) Post Transplantation
|
Evaluations for suspected GVHD, including biopsies as appropriate, during routine and/or for cause assessments.
|
From Week 1 through thirty-six months (3 Years) Post Transplantation
|
|
Number of Adverse Events
時間枠:Participant enrollment through <=thirty-six months (3 Years) Post Transplantation
|
As defined by protocol.
|
Participant enrollment through <=thirty-six months (3 Years) Post Transplantation
|
協力者と研究者
捜査官
- 主任研究者:David H. Sachs, MD、Department of Medicine, Massachusetts General Hospital
- 主任研究者:A. Benedict Cosimi, MD、Department of Medicine, Massachusetts General Hospital
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。